FDA Drug Approval: Standard, Fast Track, and Breakthrough Designations

The Agency That Stands Between Discovery and Patient

The United States Food and Drug Administration receives approximately 100–150 original new drug applications per year, but only approves 40–60 of them. Those approval decisions — made after exhaustive review of hundreds of thousands of pages of clinical and manufacturing data — determine which treatments reach American patients and under what conditions. The FDA's Center for Drug Evaluation and Research (CDER) employs over 4,000 scientists, physicians, and pharmacists to execute this responsibility. The stakes could not be higher.

Standard vs. Priority Review

Every NDA (New Drug Application) for small molecules or BLA (Biologics License Application) for biologics undergoes one of two review timelines. Standard review carries a goal of 10 months from the date the FDA accepts the application. Priority review is granted for drugs that offer major advances in treatment or provide a therapy where none existed — it shortens the review clock to 6 months. The FDA meets these Prescription Drug User Fee Act (PDUFA) targets more than 90% of the time.

Priority review is a review timeline designation, not a statement about safety or effectiveness. It means the FDA commits its resources to evaluating the application faster; it does not change the evidentiary standard. A priority review drug must demonstrate the same safety and efficacy as a standard review drug — just on a compressed timeline. The FDA also receives priority review vouchers — tradeable financial instruments (worth $100–$150 million on the open market) — for developing drugs for neglected tropical diseases and rare pediatric conditions.

Expedited Development and Review Programs

Congress and the FDA have created a suite of programs to accelerate the development and review of drugs for serious conditions with unmet medical need. These programs are often confused with one another; they have distinct eligibility criteria, mechanisms, and implications.

Fast Track Designation

Fast track designation is the broadest and easiest to obtain. A drug must address a serious or life-threatening condition and demonstrate potential to fill an unmet medical need. Fast track designation enables rolling review — the FDA evaluates completed sections of the NDA as they are submitted, rather than waiting for the full application. This can shave months from the total development timeline. Fast track also guarantees more frequent written communications and meetings with FDA staff during development.

Breakthrough Therapy Designation

Breakthrough therapy designation, created by the FDA Safety and Innovation Act of 2012, is more selective. The drug must show preliminary clinical evidence that it offers a substantial improvement over available therapy on at least one clinically significant endpoint. The designation triggers intensive guidance from senior FDA staff — including cross-disciplinary teams — and organizational commitment from the agency's leadership. Drugs with breakthrough designation receive all fast track benefits plus more proactive FDA collaboration in designing pivotal trials.

Between 2012 and 2024, the FDA granted breakthrough therapy designation to more than 700 drugs. About 20% ultimately received approval. The designation has been particularly active in oncology, where genomically targeted therapies routinely demonstrate dramatic early clinical signals.

Accelerated Approval: The Surrogate Endpoint Pathway

Accelerated approval, established in 1992 during the HIV/AIDS crisis, is the most consequential and controversial of the four programs. It allows the FDA to approve drugs based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit — without waiting for definitive evidence of actual survival or quality-of-life improvement. Tumor shrinkage, CD4 cell counts, or LDL-cholesterol reduction are examples of surrogate endpoints.

The tradeoff is explicit: post-market confirmatory trials are required to verify that surrogate improvement translates into actual clinical benefit. If confirmatory trials fail, the FDA can withdraw accelerated approval. The program accelerated access to HIV antiretrovirals in the 1990s and to numerous cancer therapies in the 2000s and 2010s. It has also been criticized for keeping ineffective drugs on the market for years while confirmatory trials were delayed — a failure the FDA's Omnibus Reform Act of 2023 attempted to address by strengthening withdrawal procedures.

The PDUFA User Fee System

The Prescription Drug User Fee Act (PDUFA), first enacted in 1992 and reauthorized approximately every five years, fundamentally transformed FDA drug review timelines. Before PDUFA, the average FDA review time for a new drug application was 30 months. Today it averages 10 months for standard review and 6 months for priority review. The mechanism: pharmaceutical companies pay fees — currently exceeding $3.5 million per full NDA submission — which fund additional FDA review staff. Approximately 40% of CDER's budget comes from user fees. The arrangement is controversial but has undeniably accelerated patient access to new medicines.

The Complete Response Letter

When the FDA determines that an NDA cannot be approved in its current form, it issues a Complete Response Letter (CRL). The CRL outlines specific deficiencies — unresolved safety questions, inadequate manufacturing data, insufficient clinical evidence — that the sponsor must address before resubmission. A CRL is not a rejection; it is a request for additional information. Some drugs receive multiple CRLs before eventually being approved; others are never resubmitted.

The CRL process underscores that FDA approval is not binary. The agency often requests additional studies, label modifications, or REMS programs as conditions of approval rather than issuing outright rejections.

Advisory Committees

For complex or controversial applications, the FDA convenes an advisory committee — an independent panel of outside experts (physicians, statisticians, patient advocates, consumer representatives) that publicly reviews the data and votes on questions posed by the FDA. Advisory committee votes and recommendations are non-binding, but the FDA historically follows them in more than 75% of cases. When it does not, it must provide written justification. Advisory committees provide a public accountability mechanism and specialized expertise beyond the FDA's own reviewers.

Risk Evaluation and Mitigation Strategies

Some drugs are approved with conditions attached. A Risk Evaluation and Mitigation Strategy (REMS) is a required safety plan for drugs where the benefits justify approval but significant risks require management. REMS programs range from simple medication guides (required for antidepressants regarding pediatric suicidality risk) to complex restricted distribution programs. The REMS for isotretinoin (iPLEDGE) requires monthly pregnancy tests and two forms of contraception because the drug causes severe birth defects. The REMS for clozapine (REMS for clozapine) requires regular monitoring for potentially fatal agranulocytosis. REMS programs affect both prescriber behavior and patient access.

The 505(b)(2) Pathway

The 505(b)(2) pathway is an abbreviated NDA route that allows sponsors to rely, at least in part, on published literature or the FDA's prior findings of safety and effectiveness for a previously approved drug. It is commonly used for reformulations (extended-release versions of existing drugs), new dosage forms, or new combinations. The 505(b)(2) route typically requires less original clinical data than a full 505(b)(1) NDA, reducing development cost and time while still requiring evidence that the new product is safe and effective for its intended use. It sits between the full NDA and the generic ANDA in terms of data requirements.

Parallel EU Approval: The EMA

The European Medicines Agency (EMA) regulates drug approvals across EU member states through a centralized procedure. While FDA and EMA approvals proceed independently and are based on separately submitted dossiers, the two agencies share scientific data through a formal collaboration program and often conduct parallel scientific advice for sponsors developing drugs in both markets simultaneously. FDA approval does not guarantee EMA approval, and vice versa — approval timelines, labeling, and required post-market commitments frequently differ.

This article is for educational purposes only. Drug approval status and regulatory pathways evolve; consult the FDA's Drugs@FDA database or qualified regulatory professionals for current information.